✦ LIBER ✦

A double blind placebo controlled trial of intravenous prostacyclin (PGI2) in 108 patients with ischaemic peripheral vascular disease

✍ Scribed by I. Virgolini; P. Fitscha; O.I. Linet; J. O'Grady; H. Sinzinger

Book ID: 119051106
Publisher: Elsevier Science
Year: 1990
Tongue: English
Weight: 575 KB
Volume: 39
Category: Article
ISSN: 0090-6980
DOI: 10.1016/0090-6980(90)90025-q

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Intravenous prostacyclin (PGI2) infusion

Intravenous prostacyclin (PGI2) infusion to 108 patients with ischaemic peripheral vascular disease: Phase II-open study

✍ I. Virgolini; P. Fitscha; K. Weiss; O.I. Linet; J. O'Grady 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 291 KB

Effects of taprostene, a chemically stab

Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: A placebo controlled double-blind trial

✍ Virgolini, I.; Fitscha, P.; O'Grady, J.; Barth, H.; Sinzinger, H. 📂 Article 📅 1989 🏛 Elsevier Science 🌐 English ⚖ 437 KB

A randomized, placebo controlled trial o

A randomized, placebo controlled trial of prostacyclin (PGI2) in peripheral arterial disease

✍ V. Hossman; A. Heinen; H. Auel; G.A. Fitzgerald 📂 Article 📅 1981 🏛 Elsevier Science 🌐 English ⚖ 688 KB

A double-blind placebo-controlled trial

A double-blind placebo-controlled trial using intravenous CGP-42446 in patients with pagets disease of bone

✍ Zelenakas, K.; Buckler, H.; Ryan, W.; Schaffer, V.; Richardson, P. 📂 Article 📅 1995 🏛 Elsevier Science 🌐 English ⚖ 70 KB

A double blind placebo-controlled trial

A double blind placebo-controlled trial using intravenous zoledronate (CGP-42446) in patients with paget’s disease of bone

✍ V. Schaffer; H. Buckler; W. Ryan; P. Richardson 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 144 KB

A double-blind, placebo-controlled singl

A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease

✍ Lisa Templeton; Andrew Barker; Keith Wesnes; David Wilkinson 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB 👁 2 views

Benzodiazepine agonists have been shown to reduce cognitive functioning by producing attentional de®cits similar to those produced by muscarinic antagonists. It has therefore been postulated that benzodiazepine antagonists may improve cognitive function in patients with Alzheimer's disease by indire